Cancer and Molecular Therapies

Dr. Eric Shifrut

Immuno-oncology & cell engineering

Adoptive T cell therapies are a new class of living drugs, achieving durable results in a subset of patients with aggressive malignancies These transformative outcomes are not shared with the majority of patients with solid tumors that remain resistant to current T cell therapies. Dr. Shifrut develops and leverages CRISPR -based platforms in primary human T cells to discover ways to engineer robust anti-tumor immunity. His goal is to design breakthrough cellbased therapies and learn how to engineer immune www.shifrut-lab.org cells to function in the suppressive tumor microenvironment His team uses lentiviral vectors, precise knock -in by CRISPR -mediated HDR and advanced experimental tools to map genetic programs that control anti-tumor immunity. The lab aims to test promising candidate perturbations in preclinical animal models of cancer immunology. His laboratory is uniquely positioned to address these translational gaps .

Dr. Shifrut, PhD, holds a joint position at the Department of Pathology, School of Medicine and the Faculty of Life Sciences at Tel Aviv University and is a principal investigator at the Tel -Aviv Sourasky Medical Center. Dr. Shifrut completed his graduate studies under the mentorship of Prof. Nir Friedman at the Weizmann Institute of Science, mapping the TCR repertoire in health and disease. For his postdoctoral training, he joined Alex Marson at UCSF and Gladstone Institutes to pioneer CRISPR discovery platforms to study primary human T cells. Shifrut’s laboratory is located at the Tel-Aviv Sourasky Medical Center.